Relapsing MS affects everyone differently. That’s why it’s important that you and your healthcare team find the treatment that’s right for you. In a-2-year clinical study, 627 people were treated with 300 mg TYSABRI and 315 people were given a placebo. TYSABRI was proven to impact relapsing MS in 3 significant ways:
83% of people treated with TYSABRI had no progression of disability (compared to 71% taking placebo)
There was a 67% reduction in the average number of relapses per year for people taking TYSABRI compared to placebo (i.e., 0.22 TYS vs 0.67 placebo)
97% of people treated with TYSABRI had no new Gd+ lesions on an MRI (compared with 72% of people taking placebo)
57% of people treated with TYSABRI had no new T2 lesions on an MRI (compared with 15% of people taking placebo)
New lesions are thought to show disease activity.
The link between brain lesions and the progression of relapsing MS has not been confirmed.